Drawing for BEGESAND

USPTO serial 79201532

BEGESAND

Reviewed by CopyMark Law Group

Reg. 5372122Status 709
Filing date
Status date
Registration date
Jan 9, 2018
Examiner
TWOHIG, SHANNON MARIE
Law office
TMO LAW OFFICE 121

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BEGESAND?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Monica Riva Talley

Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.Sterne, Kessler, Goldstein & Fox P.L.L.CWashington, DC 20005UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders; medical preparations for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders; and veterinary preparations for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders; sanitary preparations for medical purposes; dietetic food for treating viral and infectious diseases, for treating cancer, for treating immune system related diseases and disorders, for the prevention and treatment of cancer, and substances in the nature of beverages for medical or veterinary use; monoclonal antibodies and antibody mixtures for medical use, namely, diagnostic kits consisting primarily of monoclonal antibodies for use in disease testing; monoclonal antibodies for immunomodulatory treatments, in particular for the treatment of diseases mediated by the differentiation cluster 26 molecule CD26; pharmaceutical preparations comprising as active ingredient monoclonal antibodies having immunomodulatory effects, in particular for the treatment of diseases mediated by the 26 differentiation cluster molecule CD26; dietetic foods, namely, yogurt and rice-derived products, namely, rice flour adapted for medical use, dietetic beverages adapted for medical use, food supplements, enzyme food supplements, protein food supplements, protein supplements for animals, by-products of the processing of cereals for dietetic or medical use, biological preparations for medical use, biological preparations for veterinary use, pills for medicines, namely, immunosuppressant pills, chemical preparations for medical use, namely, for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, chemical preparations for veterinary use, namely, for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, biological tissue cultures for medical use, biological tissue cultures for veterinary use, enzyme preparations for medical use, enzyme preparations for veterinary use, enzymes for medical use, enzymes for veterinary use, medicines for veterinary use for the treatment of viral and infectious diseases, for the treatment of cancer, for the treatment of immune system related diseases and disorders, for the prevention and treatment of cancer, remedies for veterinary use, namely, monoclonal antibodies for immunomodulatory treatments, vaccines, veterinary products in the nature of anti-infective products for veterinary use; living tissue grafts, surgical implants composed of living tissue, radiological contrast substances for medical use, diagnostic preparations for medical use, biomarker reagents for diagnosis for medical use, adjuvants for medical use, chemical preparations for pharmaceutical use, drugs for medical use, namely, for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, pharmaceutical preparations, namely, elixirs for treating viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, plant extracts for pharmaceutical use, medicinal infusions for treating viral and infectious diseases, for treating cancer, for treating immune system related diseases and disorders, for the prevention and treatment of cancer, lotions for pharmaceutical use, medicines or human medicine for the treatment of viral and infectious diseases, for the treatment of cancer, for the treatment of immune system related diseases and disorders, for the prevention and treatment of cancer, remedies for human medicine in the nature of solution for injection for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, pharmaceutical preparations for skin care, pharmaceutical preparations for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, syrups for pharmaceutical use for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disordersSECTION 71 - CANCELLED—
010Surgical, medical, dental and veterinary apparatus and instruments, namely, infusion bag, vial, syringe; needles for medical use, medical apparatus and instruments, containers for applying medicines, namely, infusion bag, vial, syringe, hypodermic syringes, syringes for medical use, pumps for medical use, namely, infusion pumpSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 11, 2025INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Jun 24, 2025INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Jun 24, 2025INPCINVALIDATION PROCESSED—
Mar 26, 2025INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jul 26, 2024C71TCANCELLED SECTION 71—
Jan 9, 2023REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Dec 31, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jun 1, 2018FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 16, 2018FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 16, 2018FIMPFINAL DISPOSITION PROCESSED—
Apr 9, 2018FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 9, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 24, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 24, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 21, 2017GPNXNOTIFICATION PROCESSED BY IB—
Oct 4, 2017OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Oct 4, 2017OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Oct 4, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 19, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 29, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 29, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 23, 2017ALIEASSIGNED TO LIE—
Aug 2, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 24, 2017ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 24, 2017REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 18, 2017RFNTREFUSAL PROCESSED BY IB—
Feb 28, 2017RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Feb 28, 2017RFRRREFUSAL PROCESSED BY MPU—
Feb 25, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 24, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 21, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 17, 2017DOCKASSIGNED TO EXAMINER—
Feb 17, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 16, 2017REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance